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  This review seeks to find the most efficient treatment for alopecia areata. Alopecia is not very well 
understood as demonstrated by the unsatisfactory treatment options. The author reviewed many studies 
with different treatment options and concluded that treatment with Diphenylcyclopropenone (DPCP), a 
topical sensitizer, has the best results and that extensive research into the pathogenesis of alopecia areata 
is still necessary and may result in better treatment options for those afflicted with the disease. 
Alopecia Areata: an Overview 
Hair is an important part of the human presence; it is the crowning glory that sits upon one’s 
temples. Therefore, hair loss of any sort is extremely painful and embarrassing.  Most people 
automatically correlate hair loss with cancer treatments or old age. However, there is another less known 
mechanism of hair loss; alopecia areata, an autoimmune disease, causes partial or complete hair loss to 
occur. Alopecia areata affects approximately four and a half million people in the United States (Etzioni 
et.al. 2012).  The prevalence of this disease raises many questions, namely: Why does this spontaneous 
hair loss occur? Does alopecia areata occur in response to stress, or is it due to genetic factors? How can 
it be treated? 
  The Hair Cycle 
 In order to understand the nuances of the pathogenesis of alopecia areata, it is necessary to be 
familiar with the normal hair cycle. Normal hair follicles go through several stages; the anagen or 
growth phase, the catagen or regression phase, and the telogen or rest phase. Then the follicle goes 
through a fourth, shedding phase, called the exogen phase. 
 The dermal papilla of the hair follicle consists of an oval cluster of mesenchymal cells. A 
substance that is full of acid mucopolysaccharides surrounds the mesenchymal cells. The whole 
structure is at the very bottom of the follicle, and is surrounded by the matrix cells. The dermal papilla is 
responsible for initiating and directing hair growth (Alaiti, 2011). Figure 1 depicts the location of the 
dermal papilla on a healthy hair follicle. 
 
 
Figure 1- structure of hair follicle (Promocell). 
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  During the anagen phase, the dermal papilla grows (Botchkarev, Cotsarelis 2012). The hair 
matrix, of the follicle, consists of many epidermal cells that then proliferate rapidly into six different 
types of cells. These daughter cells move upward and become part of the Inner Root Sheath (IRS) and 
the Hair Shaft (HS). The HS cells shed their organelles and become stratified with bundles of 
cysteine-rich hair keratin filaments. The IRS also keratinizes by forming trichohyalin granules.  Soon 
the matrix cells cannot proliferate any further, and the follicle enters the catagen stage (Alonso, Fuchs 
2006). 
 In Catagen, the epithelial cells in the outermost epithelial layer undergo apoptosis (Botchkarev 
et.al. 1997).  The Hair bulb becomes keratinized forming a club hair. This cuts the follicle off from its 
blood supply. The club hair then travels upwards, pushed forward by a column of epithelial cells. At first 
the column of cells is thick but soon begins to shrink upward becoming secondary follicular germ cells 
(Alonso, Fuchs 2006) (Alaiti, Samer 2011).  
 After the club hair is formed, the telogen phase begins. The follicle prepares to shed the hair 
from the scalp (Botchkarev, Cotsarelis 2012). The dermal papilla and secondary germ cells form the 
telogen germinal unit.  
 Exogen is the shedding phase.  In this phase, the old hair is shed after the new anagen phase 
begins.  
 Figure 2 illustrates the four stages of the normal hair cycle. 
 
Figure 2 - The Stages of the Normal Hair Cycle (Australian Skin Clinics). 
In alopecia areata, the general hair cycle is disrupted and disfigured.  The follicles show signs 
of dystrophy in the anagen phase. This is caused by an inflammatory infiltrate that surrounds the hair 
bulb, the base of the hair follicle. The infiltrate is mainly composed of T-cells, but it also includes 
eosinophils, mast cells, plasma cells and Langerhans cells. There is also some penetration of 




papilla and hair matrix, causing apoptosis and necrosis of the follicle’s epithelium. The inflammation 
cripples the hair shaft, eventually forming the exclamation-point hairs that are associated with alopecia 
areata (Dy, Whiting 2011).   
 Although old hair is only shed after the new growth begins in healthy hair follicles, in follicles 
with alopecia areata, exogen commonly occurs before anagen begins. This results in a state where no 
visible hair fiber is left in the follicle. This state is called kenogen (McElwee, Wang 2011).  
In the most severe form of alopecia areata, all body hair is lost. This condition is referred to as 
alopecia universalis. This condition is rare. 
Diagnosis Of Alopecia Areata 
 The first step in treating any disease is to diagnose it. Alopecia areata is identified through a 
physical examination.  In its general form, alopecia areata is recognized by its typical hair loss pattern- 
causing round or oval, smooth patches of hair loss that are most noticeable on the scalp and eyebrows 
(Etzioni et.al. 2012). Figures 3a and 3b depict the pattern of hair loss triggered by alopecia areata. 
                   
Figure 3a- alopecia areata symptoms http://www.curespotbaldness.com 
Figure 3b- alopecia areata symptoms http://www.curespotbaldness.com 
First, the dermatologist will perform the “hair pull” test. The doctor will use his/her thumb and 
index fingers to gently tug at hairs in various areas of the scalp. On a healthy scalp, between 2 and 6 
hairs will detach. If more hairs fall out, that indicates excessive shedding.  The dermatologist will then 
proceed to study the hairs underneath a microscope. This is done to determine the growth phase of the 
hair. Normally, the hairs that fall out easily are in the telogen phase. Anagen roots are stronger, younger 
and still growing. If the pulled roots are in the anagen phase, this is indicative that there is a serious 
health problem (Tosti, Gray 2007) 
A newer diagnostic tool is known as videodermoscopy; it involves a high-definition video 
camera allowing for a direct, magnified examination of the scalp (Ross et.al. 2006). Videodermoscopy is 
a helpful diagnostic tool when trying to differentiate between similar diseases. In the case of alopecia, 
videodermoscopy can be used to differentiate alopecia areata from other causes of patchy alopecia. Use 
of the technology shows that in cases of alopecia areata, numerous yellow dots, known as degenerate 
follicular keratinocytes, are found on the scalp surface (Tosti, Gray 2007).  Figure 4 shows the 
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Figure 4- Alopecia areata- standard exclamation mark hairs (Tosti, Gray .2007) 
The dermatologist will also examine the patient’s nails, as alopecia areata is thought to be 
associated with nail dystrophy (Bergfeld, 2009). At times, nail distortion is one of the first signs of 
alopecia areata. Symptoms include; tiny dents on nails, white spots, lines, roughness, loss of natural 
shine, and splitting.  
Causes 
The etiology of alopecia areata is complex: determinants of the disease include genetic factors, 
psychological factors, autoimmune processes, and infectious factors. Despite active research on alopecia 
areata, investigators still have a limited understanding of its pathogenesis and etiology. 
Genetics 
 A genetic basis for alopecia areata was indicated by statistical studies which showed that 
relatives of a patient diagnosed were more likely to have the condition themselves. For example, in one 
study of 206 patients with alopecia areata, 5.5% of their immediate family members (parents, siblings, 
children) were also stricken with alopecia. Of the 206 patients, forty-five had at least one immediate 
family member with the disease (Blaumeiser et.al. 2006). 
After early statistical studies of alopecia areata showed high family-linked prevalence for the 
disease, researchers began searching for genes linked to its outbreak.  In 2011, researchers performed 
the first genome-wide association study of alopecia areata. This identified 139 significant single 
nucleotide polymorphisms (SNPs) in eight sections throughout the genome, which implicated genes of 
the immune system and the hair follicle. For example, one important find was the involvement of 
chromosome 2q33.2 (CTLA4). CTLA4 becomes displayed following T cell activation (Petukhova et.al 
2011). It is assumed that CTLA4 plays a critical role in the onset and maintenance of alopecia areata. 
CTLA4 binds CD80 and CD86 on antigen-presenting cells. One study injected monoclonal antibodies 
(mAb’s) against antigen presenting cell (APC) surface markers CD80 and CD86 as well as a 
monoclonal anti-CTLA4 antibody into mice that were predisposed to develop alopecia areata in an 
attempt to interfere with the interactions between T cells and antigen presenting cells that involve 
CTLA4. The treatment prevented the onset of the disease, proving that CTLA4 plays a big role in the 
pathogenesis of the disease  (Sundberg et al. 2011). 
Psychological Factors 
In a group of 45 patients with alopecia areata, 31 identified stressful events, including death of a 
parent, family disputes, and exams. Most events occurred less than three months before the onset of the 




event, on mice that were predisposed to develop alopecia areata. Petroleum jelly was applied to the 
mural skin to improve conductance. Then, heat was applied with a copper cylinder connected to a 
precision water bath (119.3°F) for twenty minutes daily for 12 consecutive days. Researchers then used 
an icepack to cool the area (Wikramanayake et.al. 2012). While the mice generally begin to show signs 
of alopecia at 18 months, mice that underwent the treatment developed signs of the disease at least ten 
months earlier than normal. This study suggests that stress does not cause alopecia areata to occur, but it 
may help promote onset of the disease (Wikramanayake et.al. 2010). 
One question arises from this study: Perhaps the heat itself destroys the hair follicle, and that’s 
what caused the hair loss. The study used a control; forty mice were treated with room temperature 
water. Of these mice, only 7% developed the disease. Was the higher hair loss rate in heat-treated mice 
due to the stress or to the heat itself? While it is possible that some of the hair loss was due to the heat 
itself, the presence of alopecia areata was confirmed when histological studies showed that there were 
leukocyte infiltrates in anagen hair follicles (Wikramanayake et.al. 2010). 
Autoimmunity 
 Research results overwhelmingly point to the conclusion that alopecia areata is an autoimmune 
disease. There are many indications supporting this belief:  
Firstly, as mentioned previously, a thick cluster of lymphocytic cells surrounds alopecia areata- 
affected hair follicles. These include antigen presenting cells (APCs) such as macrophages and 
Langerhans cells, which are sometimes even found within the hair follicle. 
Another reason is that alopecia areata is associated with other autoimmune diseases such as 
thyroid disorders and vitiligo (Thomas et.al. 2008). Alopecia areata also responds to immunomodulatory 
treatments such as corticosteroids, light phototherapy, and non-specific irritants such as anthralin and 
inducers of contact dermatitis (Lu et.al. 2006).  
One proposed hypothesis is that the follicles’ immune-privileged state is compromised in 
alopecia areata. Thus, normally innocuous hair-follicle-specific proteins are exposed to activated 
antigen-presenting cells. The antigen-presenting cells capture and process these proteins, which are then 
expressed on major histocompatibility complexes class II and I as antigens (Lu et.al. 2006). These 
antigens originate in the body and are known as autoantigens (Hordinsky, Ericson 2004). The exposed 
antigens activate T cells; they proliferate and travel to the skin forming the infiltrate around 
anagen-stage hair follicles, disrupting hair growth and the hair follicle dystrophy. As a result, the anagen 
phase is cut short and the follicles enter an early telogen phase. This cycle continues and hair loss occurs 
(Lu et.al. 2006).  
A few questions arise from the previous paragraph. The first question is: what stimulates the 
breakdown of immune privilege in the hair follicle? The second question is: What causes the 
dysfunction of immunoregulation that is supposed to delete autoreactive T cells? A third question is: 
which proteins function as the autoantigens in alopecia areata?  
These questions are important because their answers can give insight on how to treat the disease. 
For example, if the disease initiation were caused by loss of immune privilege in the follicle, a possible 
therapeutic mechanism would be to replace or reinforce immune privilege. This can be done through 
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promoting immune-protective cytokines and cell ligands, which reduce the exposure of follicular 
antigens (Lu et.al. 2006). 
The first two questions can be explained by genetic studies, as discussed previously. The third 
question is the subject of a lot of current research on alopecia areata. If the autoantigens involved in 
alopecia areata were identified, new treatment strategies can be developed. It could be possible to 
modify or inhibit autoantigen presentation. Another method mentioned by Lu and his co-authors would 
be to expose the immune system to such large amounts of antigen polypeptides that would then overload 
the receptors of pathogenic, autoreactive lymphocytes and could theoretically cause anergy or death of 
these cells (Lu et.al. 2006).  
However, Hordinsky and Ericson (2004), mention that an autoantibody has yet to be implicated 
in alopecia areata. Gilhar and Kalish (2006), came to the logical conclusion that the autoantigen 
involved should be melanocyte derived. This is because generally alopecia areata affects only pigmented 
hair.  
In a separate experiment, researchers used immunoperoxidase stains to test scalp samples for 
melanocyte density. They found that scalp samples from alopecia areata patients had a decreased 
number of follicular melanocytes. The researchers did not know if the decrease in melanocyte density is 
caused by the immune attack or by the rapid hair cycles that characterize the disease (Trautman et.al. 
2009). Although these results are not conclusive, they do back the theory that autoantigens in alopecia 
areata may be derived from melanocytes. 
 Another recent study isolated a structural protein, trichohyalin, as a potential autoantigen 
involved in alopecia areata, as well as Keratin 16. Researchers used mass spectrometry on ten samples; 
these showed strong reactivity to the protein trichohyalin in all alopecia areata sera (Leung et.al. 2010). 
Trichohyalin is a 200-kDa protein of the IRS. It is a doublet in some animals but is a single polypeptide 
in humans (O’Keefe et.al. 1993). Moreover, immunofluorescense studies with alopecia areata sera and a 
monoclonal antibody to trichohyalin supported the theory as the immunoreactivity in the alopecia areata 
sera was in the same location as the trichohyalin in the inner root sheath of the hair follicle (Leung et.al. 
2010). IgG tightly binds the inner root sheath and reacts with a 200/220kDa doublet by immunoblotting 
in all species studied, including canines affected by alopecia areata (Tobin et.al. 2003).  
With further research, one of the above possibilities may be implicated as the definitive 
autoantigen in alopecia areata. This would promote new treatments directed toward the autoantigen itself 
or toward the lymphocytic cells that respond to it. 
Hair-follicle-specific autoantibodies are found in the peripheral blood of individuals with the 
disease. Although some are found in normal individuals, autoantibodies such as hair-follicle specific 
IgGs are found in higher concentrations in alopecia areata patients than in non-affected individuals (Lu 
et.al. 2006). These appear to be targeting intracellular antigens. Abnormal deposits of complement and 
immunoglobulin IgG and IgM were also found in 92% of 12 patients with alopecia areata (Bystryn et.al. 
1979). These findings indicate that autoimmune processes are responsible for the hair loss associated 
with alopecia areata. 
 One study questions this theory.  In this study forty nude mice were grafted with scalp skin 




serum from patients, and the other group was given normal serum. Although deposition of 
immunoreactants such as immunoglobulins and complement was noted in hair follicles of mice who 
received patients’ serum, hair growth was observed in most cases.  The researchers concluded that 
immunoreactants do not inhibit hair growth in alopecia areata (Gilhar, Pillar 1992).  
Although hair follicle-specific antibodies may not be responsible for the initiation of alopecia 
areata, their production and presence in the hair follicle may stimulate extra damage or even maintain 
the disease.  Tobin and his colleagues performed a study to further understand the pathogenic potential 
of these antibodies. They conducted the passive transfer of serum from horses affected by alopecia 
areata into the anagen skin of C57BL/ 10 mice. Although normal hair regrowth was observed in mice 
injected with the normal serum, hair did not regrow in the area around the injection site of the alopecia 
areata serum even 13 weeks after the injection (Tobin et.al. 1998). The evidence shown here supports 
the idea that anti-hair follicle autoantibodies promote the pathogenesis of alopecia areata. 
Infectious Factors 
 The theory that alopecia areata was caused by an infectious disease was the leading theory until 
recently. In 1899, sixty-three out of sixty-nine teenage girls in a homeless shelter found bald patches on 
their heads (Bowen 1899).  In 1971, there were reports of a widespread breakout of alopecia areata 
(Messenger, McDonagh 1997).  Scientists of the time believed that alopecia areata was a contagious 
disease. 
After one study where scientists tested ten scalp biopsies for the presence of cytomegalovirus 
DNA, alopecia areata was thought to be associated with the viral infection. Out of ten samples, nine 
tested positively- leading to the belief that CMV infection leads to alopecia areata. However, in 1996, 
when the above study could not be replicated, it was determined that the first samples were 
contaminated, and that CMV has no connection to alopecia areata (Tosti et.al. 1996). The results of a 
study in year 2000 support the idea that CMV is neither a triggering factor for the immune response in 
alopecia areata nor an activator of the autoimmunity (Offidani et.al. 2000). Perhaps the teenage girls and 
other hair loss patients had another non-related disease whose side effects include hair loss. 
The etiology of alopecia areata is complex and involves many factors. It appears to have both a 
genetic and autoimmune basis. While scientists once believed that alopecia areata was itself, or was 
associated with, an infectious disease, that belief is insignificant today.  Evidence of strong family 
history trends indicates that alopecia areata is, indeed, genetically based.  Additionally, there are many 
studies that support the hypothesis that alopecia areata is an autoimmune disease and lead to the 
conclusion is that alopecia areata is mediated by autoimmune processes caused by chromosomal 
mutations in the genome. 
 Current Treatment Methods 
 Available treatments for alopecia areata include: corticosteroids, topical anthralin, topical 
minoxidil solution and contact sensitizers. Most of these therapies “bandage” the disease, stimulating 
hair growth instead of solving the immune problem. 
Corticosteroids 
 Corticosteroids have an anti-inflammatory and immunomodulatory effect. Immunomodulators 
lessen the immune system’s ability to produce antibodies that recognize and react with the antigen that 
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stimulated their production. Corticosteroids weaken the T-cell mediated immune attack on the hair 
follicle (Kumaresan M. 2010). Based on the theory that alopecia areata is carried out through attack of 
follicular autoantigens, treatment with corticosteroids should be successful at lessening the severity of 
the disease. 
Corticosteroids are heavily used in the treatment of alopecia areata.  However, their efficacy 
remains uncertain.  
In one case study, eighteen patients with severe alopecia areata were given an oral dose of 
prednisone daily. Terminal hair growth (satisfactory growth- over 50% of the scalp) occurred in seven 
patients. Upon discontinuation of the drug, all the patients had a relapse.  The researchers concluded 
that although initial growth was observed, this therapy does not produce lasting effects. Moreover, it was 
determined that the only way growth is retained after tapering the dosage or discontinuing the treatment 
is if spontaneous remission occurs (Alabdulkareem et.al. 1998). Oral corticosteroid therapy is also not 
recommended because of the adverse side effects (Nakajima et.al. 2007).  Based on these results, one 
can state that corticosteroid treatment mitigates disease symptoms while undergoing treatment but does 
not cure the disease in one case.  
The use of topical corticosteroid treatments yield slightly better results.  In one study, five out 
of twenty-eight patients (17.8%) had almost complete hair renewal after being treated with 0.05% 
Clobetasol ointment. Eleven participants experienced painful folliculitis on the treated scalp (Tosti et.al. 
2003).  Although these results aren’t excellent, the researchers noted that all participants had already 
undergone and failed to respond to topical immunotherapy. Therefore, they conclude that clobetasol 
propionate under occlusion should be listed as an effective treatment (Tosti et.al. 2003). Patients apply 
the ointment and then cover the area with plastic wrap, securing it to the skin with tape. Occlusion holds 
perspiration close to the skin, hydrating the top layer of the epidermis. Topical medications are absorbed 
into moist skin much more efficiently than with dry skin (Brannon, 2010).  
Intralesional corticosteroids have an advantage over the oral and topical treatment options; this 
treatment maximizes the effect of the corticosteroids by penetrating the skin and injecting its contents 
straight into the affected tissue (Gregoriou et.al. 2011).   
Doctors prescribe steroids with low solubility, this allows maximum action at the injection site 
for they absorb very slowly (Kumaresan, M. 2010). The most common drugs used are triamcinolone 
acetonide and betamethasone (Gregoriou et.al. 2011).  
This method of treatment works best in groups of patients who have experienced less than 75% 
scalp hair loss, who have had a shorter duration of hair loss, and in children (Kumaresan M. 2010). 
However, a study using ten participants with over 50% loss showed that the treatment does work well 
for patients with extensive loss. Six of the ten participants responded to treatment of intralesional 
triamcinolone acetonide. The researchers concluded that the reason intralesional corticosteroids are not 
generally used on patients with extensive loss is because it is painful and time consuming for the patient 
This study also mentions that the average length of the episode of alopecia areata was the same in 
responders and non-responders (Chang et.al. 2009). From this it can be determined that the treatment is 
not curative, but can interfere with the pathogenesis of the disease while in use. 




using conventional needles to apply the steroids, doctors use a multi-injection plate. There are several 
advantages to this method. Firstly, it allows for the simultaneous injection in five to seven different 
points at a fixed distance. This leads to uniformity in application, which may prevent skin atrophy.  
Treatments are followed by a gentle massage, also to help spread the steroids evenly. Another advantage 
is that the needle is long and the tip can reach the desired depth of the hair bulb where the drug is 
delivered. The disadvantage to this treatment is that the needles are large, and if not handled gently, can 
cause pain (Ferrando, Moreno-Arias 2000).  
 Although the aforementioned studies indicate that the intralesional treatment of alopecia areata is 
beneficial to those with excessive hair loss, this method is still considered the best option for patients 
with less than 50% loss (Kumaresan, M. 2010).  
Minoxidil 
 Minoxidil is an antihypertensive vasodilator known to slow the onslaught of alopecia areata and 
promote hair regrowth. Minoxidil’s exact mechanism is not known. However, tissue studies showed that 
treatment with minoxidil causes an increase of follicles in anagen and a reduction of follicles in telogen. 
This is indicated by the fact that after treatment, increased hair length is found on the forehead and other 
areas of the body that do not usually grow long hairs. The abnormal growth, referred to as 
hypertrichosis, suggests that the anagen phase of these follicles is of a longer duration (Messenger, 
Rundegren 2003). 
 Cellular uptake studies in murine follicles showed that minoxidil and minoxidil sulphate 
converged in the melanocytes and pigmented epithelial cells of the hair follicle.  This is interesting 
because previously mentioned studies implicate melanocytes as a possible source of autoantigens in 
alopecia areata. If minoxidil binds to melanocytes, and then is observed to cause an increase in hair 
growth, this observation can then serve as proof as to the role of melanocytes in the pathogenesis of 
alopecia areata.  
However, in this case, the researchers believed the reaction of minoxidil and melanin had no 
bearing on the growth that resulted, as there was no evidence of minoxidil binding to non-pigmented 
follicles although there was noted growth in both pigmented and non-pigmented follicles (Messenger, 
Rundegren 2003). This was a significant realization, as alopecia areata does not affect non-pigmented 
hair follicles. 
 Perhaps the mechanism that minoxidil uses does not include or affect the melanocytes but causes 
growth in a way that both interferes with the pathogenesis of the disease and enhances growth of healthy 
follicles as well.  Or, maybe the minoxidil and melanin connection does exist and does reverse the 
pathogenesis of the disease, as well as it enhances healthy, non-pigmented follicular growth by other 
mechanisms. This would explain why there was excessive growth noted in non-pigmented hair follicles 
as well. 
 The concentration of the active ingredient in minoxidil treatment can be varied. However, study 
results imply that the treatment is more effective when higher concentrations of minoxidil are used. In 
one experiment, forty-seven patients were treated with topical 1% minoxidil and forty-six patients were 
treated with topical 5% minoxidil. Patients with extensive hair loss showed a response rate of 38% with 
1% minoxidil, while those who received 5% minoxidil showed an 81% response rate (Fiedler-Weiss, 
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1987).   
In one double blind, placebo controlled study, researchers divided patients into two groups; eleven 
patients received 3% topical minoxidil while fourteen other patients received a placebo. Hair growth 
was observed in seven of the eleven patients (63.6%) in the minoxidil group and in five of the placebo 
group (35%). Furthermore, 27% of the minoxidil group showed cosmetically acceptable hair growth 
compared with 7.1% in the placebo group (Price, 1987). This study showed that treatment with 3% 
minoxidil results in hair growth, even though the dosage is not as strong as 5% minoxidil drugs.  
Although the topical 5% minoxidil treatment plan yields better results than the versions with lower 
concentrations, it is also known to cause hypertrichosis on the face and neck, especially in children 
(Wang et.al. 2012). Several patients also reported contact dermatitis as another adverse side effect. This 
may be the reason that most treatment plans for alopecia areata include a low concentration of topical 
minoxidil along with other drugs such as corticosteroids. 
Studies also suggest that patients with minimal hair loss have a better chance of hair renewal with this 
treatment than those patients with more hair loss. An early double-blind study observed that patients 
with severe hair loss responded more weakly to treatment of topical 1% minoxidil than those with 
moderate hair loss. Those with localized alopecia areata gained cosmetically acceptable hair regrowth 
(Gregoriou et.al. 2011).  
Anthralin 
 Treatment with anthralin is another possible option for achieving hair regrowth. In one study, 
patients with extensive alopecia areata were treated with 0.5%- 1.0% anthralin cream. As a result of the 
treatment, 25% had cosmetically acceptable hair renewal. All patients suffered from the same side 
effects: intense itchiness, scaling, and erythema on the treated area (Fiedler-Weiss, Buys 1987).  
 However, in another study, only five of fifty-one patients treated with a mixture of 5% minoxidil 
and 0.5% anthralin had cosmetically acceptable hair growth (Alsantali, 2011). While it is possible that 
the co-treatment of minoxidil and anthralin has undesirable effects, it is more likely that there are other 
factors involved. More research must be done on treatment of alopecia areata with anthralin in order to 
render this treatment worthy. 
Topical Immunotherapy 
Diphenylcyclopropenone (DPCP) is a topical sensitizer used in the treatment of alopecia areata. 
DPCP is a novel therapy because of its high success rate. It has a response rate of 60% in severe 
alopecia areata and about 88 to 100% in patients with patchy alopecia areata (Singh, Lavanya 2010).  
Perhaps its success rate is due to the fact that contact sensitization agents may modify antigen 
presenting cells. The antigen presenting cells then have trouble recognizing autoantigens. This stops the 
alopecia areata cycle (Hordinsky, Ericson 2004). 
Generally, treatment is performed on the scalp. A cotton-tipped applicator soaked with 2% 
acetone solution of DPCP is applied to an area on the scalp.  Two weeks later, a 0.001% solution of 
DPCP is applied. The solution should be retained on the scalp for forty-eight hours. The application is 
repeated weekly, increasing the concentration each time until a mild dermatitis is observed (Singh, 





 Out of fifty-four Greek alopecia areata patients that underwent immunotherapy, 83% responded.  
All research participants had extensive alopecia, or long lasting alopecia. Twenty patients experienced 
re-growth of terminal hair on the whole scalp; fifteen achieved re-growth of most terminal hair with 
some remaining patches of alopecia; nine had sparse regrowth of pigmented, terminal hair; and one 
patient observed regrowth of vellus hair. Terminal hair is dark, thick and long, while vellus hair is 
described as short, fine and barely noticeable hair. Overall, the treatment was very successful. 
Thirty-one patients had a relapse after conclusion of the treatment and underwent immunotherapy again 
(Avgerinou et.al. 2007). The relapse rate is high, but according to the researchers, this may be due to the 
failure of patients to undergo maintenance therapy once they experience cosmetically adequate regrowth 
(Gregoriou et.al. 2011).  
Topical immunotherapy can cause side effects such as persistent dermatitis, swollen lymph 
nodes and contact leukoderma (Singh, Lavanya 2010). 
Conclusions 
  Although some patients with alopecia areata have positive hair growth as a result of treatment, 
most are disappointed. Many patients who respond to treatment initially experience a relapse as soon as 
they taper the dosage or stop treatment. This is because most of the treatments that are currently 
available to patients do not rectify the problems that cause alopecia areata. Rather, they are general hair 
growth treatments that are nonspecific to alopecia areata. The best treatment option on the market today 
is immunotherapy with DPCP. This is because the mechanism that DPCP uses actually alters the cells 
that promote pathogenesis of alopecia areata. If more research is done into the etiology of alopecia 
areata, newer treatments can be developed that target the disease’s pathogenic development. 
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